CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 6, 2020 and accepted by EDGAR at May 6, 2020, 06:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $66.75bn | us-gaap:Revenues |
| Cost of revenue | 3 months2020-01-01 to 2020-03-31 | $40.35bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2020-01-01 to 2020-03-31 | $3.46bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-01-01 to 2020-03-31 | $733.0m | us-gaap:InterestExpense |
| Income tax | 3 months2020-01-01 to 2020-03-31 | $767.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-01 to 2020-03-31 | $2.01bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-01-01 to 2020-03-31 | $1.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-01 to 2020-03-31 | $1.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-01 to 2020-03-31 | 1,312,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | $3.31bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $742.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2020-01-01 to 2020-03-31 | $652.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2020-03-31 | $10.08bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $58.96bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $230.64bn | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $59.56bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $165.16bn | us-gaap:Liabilities |
| Long-term debt | At period end2020-03-31 | $65.73bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-03-31 | $5.83bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2020-03-31 | $255.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2020-03-31 | $65.14bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-20-000015. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.